June 2016—HTG Molecular Diagnostics entered into a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration will use the NGS-based HTG EdgeSeq system for use in support of Bristol-Myers Squibb’s translational research activities.
HTG Molecular Diagnostics, 877-289-2615